Gasim S, Theander T G, ElHassan A M
Centre for Medical Parasitology at Institute for Medical Microbiology and Immunology, University of Copenhagen, Denmark.
Acta Trop. 2000 Feb 25;75(1):35-8. doi: 10.1016/s0001-706x(99)00089-3.
Post kala-azar dermal leishmaniasis (PKDL) is a known sequel to visceral leishmaniasis in India and East Africa, and in Sudan about 50% of the kala-azar patients develop PKDL. In this study we followed kala-azar patients from diagnosis and up to 2 years after initiation of treatment. During the first 6 months some developed PKDL (group 1), while some did not develop PKDL (group 2). We measured the plasma levels of C-reactive protein (CRP) at diagnosis of kala-azar (day 0), during treatment (day 15), after treatment (day 30) and later during the follow up period. At day 0, plasma CRP levels were higher in patients who later developed PKDL (group 1) than in patients who did not develop PKDL subsequently (group 2) (P = 0.008). At days 15 and 30, the CRP levels were comparable in the two groups, and lower than at day 0. We have previously shown that high plasma levels of IL 10 and in keratinocytes during visceral leishmaniasis predict subsequent development of PKDL. The method however requires expensive equipment and reagents. The results of the present study indicate that kala-azar patients, who have a high risk of developing PKDL after treatment can be identified by measuring plasma CRP.
黑热病后皮肤利什曼病(PKDL)是印度和东非内脏利什曼病的一种已知后遗症,在苏丹,约50%的黑热病患者会发展为PKDL。在本研究中,我们对黑热病患者从诊断开始进行随访,直至治疗开始后2年。在最初的6个月里,一些患者发展为PKDL(第1组),而一些患者未发展为PKDL(第2组)。我们在黑热病诊断时(第0天)、治疗期间(第15天)、治疗后(第30天)以及后续随访期间测量了血浆C反应蛋白(CRP)水平。在第0天,后来发展为PKDL的患者(第1组)的血浆CRP水平高于随后未发展为PKDL的患者(第2组)(P = 0.008)。在第15天和第30天,两组的CRP水平相当,且低于第0天。我们之前已经表明,内脏利什曼病期间血浆中高水平的IL 10以及角质形成细胞中的IL 10可预测PKDL的后续发展。然而,该方法需要昂贵的设备和试剂。本研究结果表明,通过测量血浆CRP可以识别出治疗后有高风险发展为PKDL的黑热病患者。